Kestra Advisory Services LLC Sells 1,835 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Kestra Advisory Services LLC reduced its holdings in Regeneron Pharmaceuticals by 27.2%, selling 1,835 shares during the first quarter, leaving it with a total of 4,905 shares worth approximately $3.11 million.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the quarter, significantly beating the consensus estimate of $8.43 and showing a 3.6% increase in revenue year-over-year.
• Analysts have varying ratings on Regeneron Pharmaceuticals, with target prices ranging from $580.00 to $890.00, while it maintains an average rating of "Moderate Buy".

Kestra Advisory Services LLC lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 27.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,905 shares of the biopharmaceutical company's stock after selling 1,835 shares during the quarter. Kestra Advisory Services LLC's holdings in Regeneron Pharmaceuticals were worth $3,111,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of REGN. Brighton Jones LLC raised its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares during the period. American Assets Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $427,000. Integrated Wealth Concepts LLC raised its holdings in Regeneron Pharmaceuticals by 55.5% in the 4th quarter. Integrated Wealth Concepts LLC now owns 1,163 shares of the biopharmaceutical company's stock worth $828,000 after acquiring an additional 415 shares during the period. Lido Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 9.5% in the 4th quarter. Lido Advisors LLC now owns 2,314 shares of the biopharmaceutical company's stock worth $1,649,000 after acquiring an additional 201 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 475.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 22,388 shares of the biopharmaceutical company's stock worth $15,948,000 after acquiring an additional 18,496 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $586.96 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm's 50-day simple moving average is $554.52 and its 200-day simple moving average is $589.43. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,210.97. The firm has a market cap of $62.21 billion, a P/E ratio of 14.79, a price-to-earnings-growth ratio of 1.96 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the business earned $11.56 EPS. The firm's revenue was up 3.6% on a year-over-year basis. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. BMO Capital Markets lifted their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Citigroup restated a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research report on Friday, August 1st. Morgan Stanley restated an "overweight" rating and issued a $761.00 price target (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.